USP strongly supports Biden Administration’s leadership and actions to strengthen medicines supply chain

Media Contact
Anne Bell:
Office: +1-301-998-6785
Mobile: +1-240-701-3242

Rockville, MD, June 14, 2021 – The United States Pharmacopeia (USP) applauds the Biden Administration’s continued leadership to elevate issues facing America’s medicines supply chain. We commend the announcement of new actions to address vulnerabilities in, and strengthen the resilience of, these supply chains essential to the health and security of Americans.

A core pillar of USP’s mission is to help strengthen the global supply chain so that the medicines people rely on for their health are available when needed and work as expected. An independent scientific organization with over 200 years of experience in the quality of medicines and active pharmaceutical ingredients both domestically and globally, USP supports efforts to strengthen the production of critical medicines. To increase production capability and capacity, USP believes that public-private partnerships can play a significant role in helping reduce barriers to the adoption of innovations and novel platforms such as advanced pharmaceutical manufacturing technologies. USP is also working to identify risks in the upstream supply chain to enable better avoidance of downstream impact on patients and improve supply chain resilience. Information that helps mitigate supply chain risks is vital for informing investments, policy reforms, or other actions for building greater resilience.

“The Administration is to be commended for moving swiftly to establish a sustained federal commitment to strengthening America’s medicines supply chain and recognizing that consultation with stakeholders is crucial to achieving this goal,” said Ronald T. Piervincenzi, Ph.D., CEO of USP. “We stand ready to support and work with the Administration and other stakeholders on ensuring public trust in a strong and resilient medicine supply chain.”